GlaxoSmithKline plc Given Average Rating of “Hold” by Brokerages (LON:GSK)
Shares of GlaxoSmithKline plc (LON:GSK) have been given a consensus recommendation of “Hold” by the twenty-two ratings firms that are covering the stock, Stock Ratings Network.com reports. Four analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is GBX 1,641.76 ($27.54).
GlaxoSmithKline plc (LON:GSK) opened at 1386.50 on Wednesday. GlaxoSmithKline plc has a 52 week low of GBX 1200.668 and a 52 week high of GBX 1706.00. The stock’s 50-day moving average is GBX 1504. and its 200-day moving average is GBX 1590.. The company’s market cap is £66.607 billion.
The company also recently declared a dividend, which is scheduled for Thursday, October 2nd. Investors of record on Wednesday, August 6th will be given a dividend of GBX 19 ($0.32) per share. This represents a yield of 1.28%. The ex-dividend date of this dividend is Wednesday, August 6th.
A number of analysts have recently weighed in on GSK shares. Analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday. They now have a GBX 1,385 ($23.23) price target on the stock. Separately, analysts at Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th. Finally, analysts at Shore Capital reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.